Gene: SV2C

22987
-
synaptic vesicle glycoprotein 2C
protein-coding
5q13.3
Ensembl:ENSG00000122012 MIM:610291 Vega:OTTHUMG00000162384 UniprotKB:Q496J9
NC_000005.10
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.373e-1 (AD)  7.351e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg07353583chr5:75471166SV2CGene body3.455e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC9A70.813
SYT20.785
HS6ST20.782
PAQR90.776
C4orf500.773
PPM1E0.758
RPS6KA60.757
FAM78B0.754
SCN8A0.754
CDH70.752

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ROM1-0.514
MYL3-0.508
CSAG1-0.495
NFIA-0.483
AGTRAP-0.48
COPZ2-0.479
CDKN2C-0.479
RAB13-0.469
TMEM176A-0.459
PXDC1-0.456

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SV2C gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SV2C mRNA16483693
D001151ArsenicArsenic affects the methylation of SV2C gene25304211
C015001arsenitearsenite results in increased methylation of SV2C promoter23974009
D001280AtrazineAtrazine results in decreased expression of SV2C mRNA25929836
C006780bisphenol A[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SV2C promoter23359474
C006780bisphenol Abisphenol A results in decreased expression of SV2C mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of SV2C mRNA29097150
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SV2C mRNA22079614
D003993Dibutyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SV2C promoter23359474
D019422Dietary SucroseDietary Sucrose results in increased expression of SV2C mRNA26033743
D004051Diethylhexyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SV2C promoter23359474
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of SV2C mRNA29097150
C042720mercuric bromidemercuric bromide results in decreased expression of SV2C mRNA26272509
D008694Methamphetamine[Methamphetamine co-treated with SCH 23390] results in increased expression of SV2C mRNA19564919
D008694MethamphetamineMethamphetamine results in increased expression of SV2C mRNA19564919
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SV2C mRNA28001369
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of SV2C mRNA23179753
D009532NickelNickel results in decreased expression of SV2C mRNA25583101
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of SV2C mRNA26272509
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SV2C mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of SV2C mRNA26272509
C006253pirinixic acid[pirinixic acid co-treated with PPARA] results in increased expression of SV2C mRNA20813756
C006253pirinixic acidpirinixic acid results in increased expression of SV2C mRNA20813756
D010936Plant ExtractsPlant Extracts results in decreased expression of SV2C mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of SV2C mRNA24780913
C534628SCH 23390[Methamphetamine co-treated with SCH 23390] results in increased expression of SV2C mRNA19564919
C534628SCH 23390SCH 23390 results in increased expression of SV2C mRNA19564919
C017947sodium arsenitesodium arsenite affects the methylation of SV2C gene28589171
C032910triadimefontriadimefon results in decreased expression of SV2C mRNA26790661
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of SV2C mRNA26272509
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of SV2C mRNA"26743178
D014635Valproic AcidValproic Acid results in increased expression of SV2C mRNA23179753|2718838
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SV2C mRNA"27188386
C111237vorinostatvorinostat results in increased expression of SV2C mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI24240280  
GO:0022857transmembrane transporter activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006836neurotransmitter transport-IEA-  
GO:0007268chemical synaptic transmission-IEA-  
GO:0055085transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0008021synaptic vesicle-TAS15217342  
GO:0016021integral component of membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
GO:0030054cell junction-IEA-  
GO:0030672synaptic vesicle membrane-IBA21873635  
GO:0030672synaptic vesicle membrane-TAS-  
GO:0043005neuron projection-IBA21873635  
KEGG ID KEGG Term
hsa04512ECM-receptor interaction
Reactome ID Reactome Term Evidence
R-HSA-1643685DiseaseTAS
R-HSA-168799Neurotoxicity of clostridium toxinsTAS
R-HSA-5250955Toxicity of botulinum toxin type D (BoNT/D)TAS
R-HSA-5250968Toxicity of botulinum toxin type A (BoNT/A)TAS
R-HSA-5250981Toxicity of botulinum toxin type F (BoNT/F)TAS
R-HSA-5339562Uptake and actions of bacterial toxinsTAS
R-HSA-5663205Infectious diseaseTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23032990A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. (2013 Dec)Hill-Burns EMPharmacogenomics J